SOURCE: BioMedical Technology Solutions Holdings

October 06, 2009 17:24 ET

BMTS Announces Pilot In-Store Demolizer® II Sharps Disposal Program

ENGLEWOOD, CO--(Marketwire - October 6, 2009) - Biomedical Technology Solutions Holdings, Inc. ("BMTS" or the "Company") (www.bmtscorp.com) (OTCBB: BMTL) is pleased to announce the BMTS in-store Demolizer® II Sharps Disposal Program and the placement of its first Demolizer® II in a Kroger pharmacy. This program is designed to establish a valuable, full service sharps life cycle solution to pharmacy syringe customers. With over 2000 retail pharmacy outlets in the U.S., the placement of the first system in a Kroger pharmacy is an important benchmark for BMTS.

BMTS believes this program will help to build national awareness of the growing public health and environmental problems associated with the improper or unsafe transportation and disposal of sharps waste generated at home. By establishing a safe, environmentally friendly and convenient in-store disposal method BMTS hopes to encourage the estimated 9 million people in the U.S. that administer 3 billion injections at home annually to take advantage of the in-store Demolizer® II sharps disposal program.

The first of its kind, this in-store sharps disposal program provides a safe and environmentally friendly biomedical waste disposal alternative designed to enable diabetics and others using syringes at home to safely destroy their sharps waste by bringing it back to their pharmacy when replenishing treatment supplies.

Don Cox, President and CEO of BMTS, explains, "The ultimate goal of the in-store Demolizer® II sharps disposal program is to establish the Demolizer® II as the preferred sharps disposal system in the pharmacy market. The faster we expand our brand presence, the sooner we can start reaping financial rewards from our patented Demolizer® technology in the pharmacy program, while at the same time reducing the negative public and environmental impact of improper disposal."

About Biomedical Technology Solutions Holdings, Inc.

Biomedical Technology Solutions Holdings, Inc., located in Englewood, Colorado, sells the Demolizer® II through its wholly owned subsidiary Biomedical Technology Solutions, Inc. BMTS' patented Demolizer® Technology converts infectious biomedical waste into non-infectious material. BMTS' products provide biomedical waste treatment solutions for the over 1,000,000 low to medium volume medical waste generators in the US and a global market five times larger than the US. For more information, visit our investor relations page at www.bmtscorp.com.

About the Demolizer® II

The Demolizer® II is the GREEN alternative to biomedical waste disposal. The device is the only patented, portable, and self-contained system able to process both sharps and typical red bag biomedical waste onsite. The processed waste is rendered sterile and discarded as common trash eliminating up to 100% of the cost associated with its disposal. The Demolizer® II meets or exceeds all EPA and CDC guidelines and is approved or meets treatment requirements in 47 states after review by 78 governmental agencies. The device uses no chemicals or liquids, plugs into a normal outlet through a surge protector, and automatically records and prints state required documentation. The Demolizer® II provides a safer, more environmentally GREEN method for biomedical waste disposal.

Safe Harbor for Forward-Looking Statements

The statements contained in this press release may include certain projections and forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve a number of risks and uncertainties. Such statements reflect the Company's current views with respect to future events and financial performance. No assurances can be given however, that these events will occur or that such expectations will be achieved and that actual results could differ materially from those described. Actual results of future operations of Biomedical Technology Solutions Holdings, Inc. may differ materially from those indicated by these forward-looking statements as a result of various important factors.

Contact Information

  • Contact:
    Union Investor Relations
    Ian Shanno
    (310) 928-3780
    is@unionir.com